Business Wire

FPT Co-hosted France-Vietnam Business Forum, Emphasising a Sustainable Future Driven by Technology

Share

FPT Corporation (FPT), in collaboration with MEDEF International, Business France, the French Chamber of Commerce and Industry (CCIFV), and French Foreign Trade Advisors (CCE), recently organized the France-Vietnam Business Forum in Paris, France. Gathering leading business leaders and tech experts, the event covered topics aiming at accelerating the economic dynamism between Vietnam and France, targeting core industries of both sides, such as aerospace, automotive, manufacturing, energy, and healthcare.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527659801/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The event was attended by the Vietnamese Ambassador to France, Dinh Toan Thang, Business France, MEDEF International, CCI France Vietnam, French Foreign Trade Advisors, and over 100 high-level government officials, business leaders, and tech experts. (Photo: Business Wire)

“Vietnam is one of France’s main economic partners in Southeast Asia, covering a diverse array of sectors with increasing import of Vietnam’s specialised electronic and textile products. In terms of investment, France is the second largest European (EU) investor in Vietnam, generating 50,000 jobs for this market. In 2023, Business France also supported nine Vietnamese investment projects in France,” said Laurent Saint-Martin, CEO of Business France.

Featuring panelists from global businesses and organizations like NVIDIA, FPT, Egis, Thales, Oerlikon, Valeo, OPmobility, and more, the business forum offered attendees the latest updates in next-gen technology and the national socio-economic outlook. Key topics included the economic attractiveness of France and Vietnam, Vietnam’s momentum as a global digital and investment hub, ethical innovation in artificial intelligence, and smart mobility for a sustainable future.

Throughout the panel discussions, FPT has showcased its broad expertise, industry experience, and extensive global outreach, reaffirming its position as a sustainable transformative enabler with cutting-edge and green technologies.

“Vietnam is emerging as a workforce powerhouse and a global hub for investment and technology, notably in digital transformation and green transition, as well as the advancement of AI and the automotive industry. As the country’s leading corporation, FPT’s strategic directions align with the French government and businesses. We have a robust partnership network, a highly skilled workforce, and a solid global presence to bridge the friendship and cooperation between Vietnam and France’s enterprises,” said Pham Minh Tuan, FPT Executive Vice President and FPT Software CEO.

“FPT is the perfect illustration of what France and Vietnam can achieve together. Their 15 years of presence in France with continuous investments since 2008 have created over 120 jobs and the establishment of three subsidiaries. Their renewed strategic partnership with Airbus in 2021 is also an evident symbol of effective cooperation with the European industrial sector,” Laurent added.

FPT now has over 100 local experts working in France's major cities and 500 offshore professionals in Vietnam, focusing on AI, Big Data, BI, SAP, DevSecOps, Cloud, and AUTOSAR services. Its robust competencies are recognized through strategic partnerships with more than 50 French giants across industries.

As part of the company’s global expansion, FPT has been actively involved in M&A deals to amplify its offshore delivery capabilities and local footprint, notably the recent acquisition of an 80% stake in the French IT consulting firm AOSIS. Last year, its French subsidiary also entered the Top 100 ICT Companies in France, targeting to enter the top 50 by 2028.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions21.6.2024 21:45:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. At baseline, all patients in the study had undetectable fasting C-peptide (a marker of endogenous insulin secretion), a history of recurrent SHEs in the year prior to screening, and required an average of 39.3 (min, max; 19.8, 52.0) units of insulin per day. Following a single infusion of VX-880 at the full dose, all 12 patients demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90. At the latest visi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye